WellStar Clinical Partners ACO Quality Measures Tip Sheet

|  |  |
| --- | --- |
| **Measure** | **ACO/MIPS QUALITY MEASURES TIP SHEET FOR CALENDAR YEAR 2024:**  **Documentation needed in chart to validate completed quality measures (Asterisked (\*) items can be documented by any member of the treatment team.)** |
| ACO-13 (Care-2):  **Screen for Future Fall Risk** (Pts aged 65 or older) | ⃝ Evidence that the patient has been asked, “have you had any falls/falls with injury in the year 2024?”\* OR a completed fall screening tool in chart, as long as it addresses any falls/falls with injury, especially within CY2024\* or gait or balance assessed during measurement period  ⃝ Statement of “no falls” meets the measure |
| ACO-20 (Prev-5):  **Screen for Breast Cancer** (Women aged 40-74 Years) | ⃝ Mammogram report in chart, including date/results, OR provider note in chart stating that mammogram has been done, including date/results, between Oct. 1, 2022 and Dec. 31, 2024  ⃝ Patient reported data is acceptable as long as it includes full date (M/D/Y), type of test and results are documented in the chart  ⃝ Excluded: women with hx of bilateral or two unilateral mastectomies |
| ACO-19 (Prev-6):  **Screen for Colorectal** Cancer (Pts aged 45-75 years) | ⃝ Screening date and result must be documented in the chart, either by final report/lab result, physician note, or patient reported data including full date of type of test (M/D/Y) and result (minimally documented as “normal” or “abnormal”) for any of the following tests:   * FOBT during calendar year 2024 OR * FIT-DNA screening/Cologuard between Jan. 1, 2022 and Dec. 31, 2024 OR * Flexible sigmoidoscopy between Jan. 1, 2020 & Dec. 31, 2024 OR * Colonoscopy between Jan. 1, 2015 & Dec. 31, 2024 OR * CT Colonography between Jan. 1, 2020 and Dec. 31, 2024 |
| ACO-14 (Prev-7):  **Flu Vaccine** | ⃝ Evidence of flu immunization given between August 2023 and March 31, 2024 along with flu immunization August 2024 and December 2024 (current/most recent flu season)\* (Pt/caregiver reported information meets the measure) |
| ACO-17 (Prev-10):  **Tobacco Use & Quit Advice 12 years & Older** | ⃝ Patient was screened for **tobacco use** (not just smokers) one or more times in CY2024  ⃝ ***IF*** a tobacco user (smoking, pipe, smokeless tobacco “chewing tobacco”) found on most recent screening, documentation of brief cessation counseling (3 minutes or less), and/or pharmacotherapy completed. Cessation is during the measurement period or 6 months prior to the measurement period. |
| ACO-18 (Prev-12)  **Depression Screen & Follow Up** | ⃝ MUST include the name of screening tool used (Wellstar Epic uses PHQ2/PHQ9/PHQ-A)\*  ⃝ Patients screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized tool AND if positive, a follow-up plan is documented on the date of or up to two days after the date of the qualifying encounter  ⃝ If screen is positive, follow up must be documented and must include at least one of the following:\*   * Referral to a practitioner who is qualified to diagnose & treat depression * Pharmacological interventions * Other interventions or follow-up for the dx & tx of depression * ***Exclusion: Bipolar Diagnosis or Patient Refuse to complete or Medical reason for not screening (must be documented in note)*** |
| ACO-42 (PREV-13):  **Statin Therapy for the Prevention and Treatment of Cardiovascular Disease** | ⃝ For a patient in any one of the four categories listed below, there is documentation that the  patient was prescribed or was already on statin medication therapy during calendar year 2024:   1. All patients who were previously diagnosed with or currently have an   active diagnosis of clinical atherosclerotic cardiovascular disease   1. Adult patients aged 20 to 75 years who have ever had a LDL-C level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia 2. Patients aged 40 to 75 years with a diagnosis of diabetes. 3. Patients aged 40 to 75 years at the beginning of the measurement period with a 10- year ASCVD risk score of >20 percent during the measurement period.  * ***EXCEPTIONS for Statin use:*** * ***Statin -associated muscle symptoms (SAMS) or allergy to statin medication*** * ***Active liver disease or hepatic disease or insufficiency*** * ***Documentation of a medical reason for not being prescribed statin therapy*** |
| ACO-27 **Diabetes H A1c**  **Poor Control** (>9%) Pts aged 18-75 years | ⃝ If patient has diabetes, Hemoglobin A1c has been completed within CY2023  ⃝ Looks for levels >9% (“Reverse” measure – Lower numbers are better) |
| ACO-28 (HTN-2)  **Controlling HBP in pts. With hypertension** (age 18-85 years of age) | ⃝ Diagnosis of essential hypertension starting before and continuing into or starting during the first six months of the measurement period (1/1/2024- 6/30/2024).  ⃝ BP recorded at most recent office visit during calendar year 2024\* *-- For Telehealth visits, example documentation “patient-reported BP via a home device during telehealth visit.”*  ⃝ “Controlled” for this measure is <140 systolic AND <90 diastolic |
| ACO-40 (MH-1): **For pts.**  **With Depression: Remission at 12 (+/- 60 days) Months** | ⃝ If patient has a documented PHQ9 score of > 9 between November 1, 2022 and October 31, 2023, this measure then looks for:  ⃝ Documented PHQ9 score of < 5 between 10 and 14 months after the initial PHQ9 score of >9.   * ***EXCLUSIONS include patients with a diagnosis of bipolar disorder*** * ***EXCEPTIONS include*** documentation of medical reason for not screening for depression (cognitive, functional, or motivational limitations, etc.) |

WellStar Clinical Partners ACO; Revised 01.26.2024